Sustainability Report

Overview

The report describes ADVANZ PHARMA's 2024 ESG performance across patient access, climate and people. It highlights the first-time calculation and disclosure of Scope 3 value-chain emissions, alongside a 13.1% reduction in Scope 1 and 2 emissions and renewable electricity usage of 65.2%. The company reported 702 employees, 50.3% female workforce representation and 40% female representation in management and above positions. The report also presents a double materiality assessment aligned with anticipated CSRD requirements and uses the VSME Basic Module as its guiding reporting framework.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024-2025
Period: 1 January 2024 – 31 December 2024
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services